Form 8-K

8-K — BECTON DICKINSON & CO

Accession: 0001628280-26-023185

Filed: 2026-04-02

Period: 2026-04-02

CIK: 0000010795

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — bdx-20260402.htm (Primary)

EX-99.1 (ex991042026.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: bdx-20260402.htm · Sequence: 1

bdx-20260402

0000010795false00000107952026-04-022026-04-020000010795us-gaap:CommonStockMemberexch:XNYS2026-04-022026-04-020000010795bdx:Notes1.900dueDecember152026Memberexch:XNYS2026-04-022026-04-020000010795bdx:Notes1.208dueJune42026Memberexch:XNYS2026-04-022026-04-020000010795bdx:Notes1213DueFebruary122036Memberexch:XNYS2026-04-022026-04-020000010795bdx:Notes3.519DueFebruary82031Memberexch:XNYS2026-04-022026-04-020000010795bdx:Notes3.828DueJune72032Memberexch:XNYS2026-04-022026-04-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 2, 2026

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802 22-0760120

(Commission File Number) (IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes,

New Jersey

07417-1880

(Address of Principal Executive Offices) (Zip Code)

(201)

847-6800

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol

Name of each exchange on

which registered

Common stock, par value $1.00 BDX New York Stock Exchange

1.900% Notes due December 15, 2026 BDX26 New York Stock Exchange

1.208% Notes due June 4, 2026 BDX/26A New York Stock Exchange

1.213% Notes due February 12, 2036 BDX/36 New York Stock Exchange

3.519% Notes due February 8, 2031 BDX31 New York Stock Exchange

3.828% Notes due June 7, 2032 BDX32A New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

As previously disclosed, on February 9, 2026, Becton, Dickinson and Company (“BD”) completed the spin-off of its Biosciences and Diagnostic Solutions business and combination of the business with Waters Corporation. In order to assist investors, BD has furnished as Exhibit 99.1 recast historical financial information, which reflects the presentation of BD's former Biosciences and Diagnostics Solutions business as discontinued operations to provide a historical baseline of BD’s standalone operating results from continuing operations and excluding specified items.

The information furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). Details regarding these non-GAAP measures and adjustments can be found in the schedules furnished as Exhibit 99.1.

The information contained in this Current Report on Form 8-K and Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 BD Unaudited Recast Financial Information, which is furnished pursuant to Item 2.02.

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY

(Registrant)

By: /s/ Stephanie M. Kelly

Stephanie M. Kelly

Chief Securities and Governance Counsel, Corporate Secretary

Date: April 2, 2026

EX-99.1

Filename: ex991042026.htm · Sequence: 2

Document

Exhibit 99.1

Non-GAAP Financial Measures Included in the Financial Tables

The unaudited financial information included herein contains certain financial measures that differ from those presented in accordance with generally accepted accounting principles in the United States ("non-GAAP measures"). These non-GAAP measures include adjustments to certain line items in the attached recast historical financial information to adjust for purchase accounting adjustments; integration, restructuring, and transaction costs; financing impacts; separation-related items; certain regulatory costs; certain product, litigation, and other items; and the income tax benefit of these items, which affect the comparability of period-over-period calculations of diluted earnings per share. In particular, adjustments for fiscal year 2024 exclude the impact of European regulatory initiative-related costs, which represent costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation (collectively, the “New EU Medical Devices Regulations”), which represent a significant, unusual change to the existing regulatory framework. We consider the excluded European regulatory initiative-related costs to be duplicative of previously incurred costs and/or one-off costs related to establishing initial compliance with such regulatory regimes, and in each case are limited to a specific period of time. These expenses relate to establishing initial compliance with the New EU Medical Devices Regulations and include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. These costs were primarily recorded in Cost of products sold and Research and development expense. These adjustments are consistent with the adjustments made by BD when it reported its operating results for the periods presented.

BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD’s underlying operational results or that affect period-to-period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the Company’s performance, especially when comparing such results to prior periods or forecasts. We believe presenting such measures provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Earnings per share amounts presented are calculated from the underlying amounts.

Page 1

BECTON DICKINSON AND COMPANY

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Fiscal Year 2026 Fiscal Year 2025 Fiscal Year 2024

Three Months Ended December 31, 2025 Three Months Ended December 31, 2024 Three Months Ended March 31, 2025 Three Months Ended June 30, 2025 Three Months Ended September 30, 2025 Twelve Months Ended September 30, 2025 Twelve Months Ended September 30, 2024

REVENUES $ 4,486 $ 4,333 $ 4,480 $ 4,726 $ 5,005 $ 18,544 $ 16,820

Cost of products sold 2,434 2,536 2,619 2,490 2,639 10,285 9,372

Selling and administrative expense 1,229 1,155 1,117 1,163 1,208 4,643 4,250

Research and development expense 235 243 232 230 264 970 896

Integration, restructuring and transaction expense 108 89 93 96 125 403 365

Other operating expense, net 13 28 35 7 232 302 223

TOTAL OPERATING COSTS AND EXPENSES 4,018 4,051 4,097 3,986 4,469 16,603 15,106

OPERATING INCOME 468 282 383 740 536 1,941 1,713

Interest expense (153) (155) (150) (152) (155) (613) (528)

Interest income 4 22 5 4 4 35 162

Other expense, net (7) (13) (36) (23) (33) (105) (20)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 311 136 201 568 352 1,258 1,327

Income tax provision (benefit) 1 (10) 43 118 7 158 273

NET INCOME FROM CONTINUING OPERATIONS 311 147 158 450 346 1,100 1,054

Income from discontinued operations, net of tax 71 157 150 123 148 577 651

NET INCOME $ 382 $ 303 $ 308 $ 574 $ 493 $ 1,678 $ 1,705

BASIC EARNINGS PER SHARE

Income from Continuing Operations $ 1.09 $ 0.51 $ 0.55 $ 1.57 $ 1.21 $ 3.83 $ 3.64

Income from Discontinued Operations 0.25 0.54 0.52 0.43 0.51 2.01 2.25

Basic Earnings per Share $ 1.34 $ 1.05 $ 1.07 $ 2.00 $ 1.72 $ 5.83 $ 5.88

DILUTED EARNINGS PER SHARE

Income from Continuing Operations $ 1.09 $ 0.50 $ 0.55 $ 1.57 $ 1.20 $ 3.81 $ 3.62

Income from Discontinued Operations 0.25 0.54 0.52 0.43 0.51 2.00 2.24

Diluted Earnings per Share $ 1.34 $ 1.04 $ 1.07 $ 2.00 $ 1.72 $ 5.82 $ 5.86

AVERAGE SHARES OUTSTANDING (in thousands)

Basic 285,582 289,505 287,293 287,170 286,612 287,648 289,763

Diluted 285,845 290,389 287,737 287,223 287,118 288,509 291,009

Page 2

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

Three Months Ended December 31, 2025

Reported (GAAP) Purchase accounting adjustments

(A) Integration costs

(B) Restructuring costs

(B) Separation-related items

(D) Product, litigation, and other items

(E) TSA/LSA total Income tax benefit of special items Adjusted (Non-GAAP)

See Footnotes on Page 10

REVENUES $ 4,486 $ — $ — $ — $ — $ — $ — $ — $ 4,486

Gross margin 2,052 384 — — — — — — 2,436

Selling and administrative expense 1,229 — — — — (6) — — 1,223

Research and development expense 235 — — — — (3) — — 232

OPERATING INCOME 468 384 36 71 1 19 (2) — 978

Net interest expense (149) (1) — — — — — — (150)

Other (expense) income, net (7) — — — — (11) 2 — (17)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 311 383 36 71 1 8 — — 811

Income tax provision 1 — — — — — — 95 95

NET INCOME FROM CONTINUING OPERATIONS $ 311 $ 383 $ 36 $ 71 $ 1 $ 8 $ — $ (95) $ 716

DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS $ 1.09 $ 1.34 $ 0.13 $ 0.25 $ 0.01 $ 0.03 $ — $ (0.33) $ 2.50

Page 3

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

Three Months Ended December 31, 2024

Reported (GAAP) Purchase accounting adjustments

(A) Integration costs

(B) Restructuring costs

(B) Transaction costs

(E) TSA/LSA total Income tax benefit of special items Adjusted

(Non-GAAP)

See Footnotes on Page 10

REVENUES $ 4,333 $ — $ — $ — $ — $ — $ — $ — $ 4,333

Gross margin 1,797 562 — — — 28 — — 2,387

Selling and administrative expense 1,155 (1) — — — (9) — — 1,145

Research and development expense 243 — — — — (8) — — 235

OPERATING INCOME 282 563 24 62 3 75 (3) — 1,005

Net interest expense (133) (1) — — — — — — (134)

Other (expense) income, net (13) — — — — (3) 3 — (14)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 136 562 24 62 3 72 — — 858

Income tax (benefit) provision (10) — — — — — — 61 51

NET INCOME FROM CONTINUING OPERATIONS $ 147 $ 562 $ 24 $ 62 $ 3 $ 72 $ — $ (61) $ 808

DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS $ 0.50 $ 1.93 $ 0.08 $ 0.21 $ 0.01 $ 0.25 $ — $ (0.21) $ 2.78

Page 4

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

Three Months Ended March 31, 2025

Reported (GAAP) Purchase accounting adjustments

(A) Integration costs

(B) Restructuring costs

(B) Product, litigation, and other items

(E) TSA/LSA total Income tax benefit of special items Adjusted

(Non-GAAP)

See Footnotes on Page 10

REVENUES $ 4,480 $ — $ — $ — $ — $ — $ — $ 4,480

Gross margin 1,861 544 — — 87 — — 2,492

Selling and administrative expense 1,117 — — — 9 — — 1,126

Research and development expense 232 — — — (2) — — 230

OPERATING INCOME 383 544 26 66 115 (3) — 1,133

Net interest expense (146) (1) — — — — — (147)

Other (expense) income, net (36) — — — 24 3 — (9)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 201 543 26 66 139 — — 977

Income tax provision 43 — — — — — 129 173

NET INCOME FROM CONTINUING OPERATIONS $ 158 $ 543 $ 26 $ 66 $ 139 $ — $ (129) $ 804

DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS $ 0.55 $ 1.89 $ 0.09 $ 0.23 $ 0.48 $ — $ (0.45) $ 2.79

Page 5

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

Three Months Ended June 30, 2025

Reported (GAAP) Purchase accounting adjustments

(A) Integration costs

(B) Restructuring costs

(B) Transaction costs

(E) TSA/LSA total Income tax benefit of special items Adjusted

(Non-GAAP)

See Footnotes on Page 10

REVENUES $ 4,726 $ — $ — $ — $ — $ — $ — $ — $ 4,726

Gross margin 2,235 377 — — — (1) — — 2,612

Selling and administrative expense 1,163 — — — — (20) — — 1,143

Research and development expense 230 — — — — (2) — — 228

OPERATING INCOME 740 378 37 57 1 26 (3) — 1,237

Net interest expense (148) (1) — — — — — — (149)

Other (expense) income, net (23) — — — — 18 3 — (2)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 568 376 37 57 1 44 — — 1,085

Income tax provision 118 — — — — — — 83 201

NET INCOME FROM CONTINUING OPERATIONS $ 450 $ 376 $ 37 $ 57 $ 1 $ 44 $ — $ (83) $ 884

DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS $ 1.57 $ 1.31 $ 0.13 $ 0.20 $ 0.01 $ 0.15 $ — $ (0.29) $ 3.08

Page 6

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

Three Months Ended September 30, 2025

Reported (GAAP) Purchase accounting adjustments

(A) Integration costs

(B) Restructuring costs

(B) Separation-related items

(D) Product, litigation, and other items

(E) TSA/LSA total Income tax benefit of special items Adjusted

(Non-GAAP)

See Footnotes on Page 10

REVENUES $ 5,005 $ — $ — $ — $ — $ — $ — $ — $ 5,005

Gross margin 2,366 384 — — — 1 — — 2,751

Selling and administrative expense 1,208 — — — — (13) — — 1,195

Research and development expense 264 — — — — (3) — — 261

OPERATING INCOME 536 384 41 84 3 247 (4) — 1,292

Net interest expense (151) (1) — — — — — — (152)

Other (expense) income, net (33) — — — — 3 4 — (26)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 352 383 41 84 3 250 — — 1,114

Income tax provision 7 — — — — — — 170 177

NET INCOME FROM CONTINUING OPERATIONS $ 346 $ 383 $ 41 $ 84 $ 3 $ 250 $ — $ (170) $ 937

DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS $ 1.20 $ 1.33 $ 0.14 $ 0.29 $ 0.01 $ 0.87 $ — $ (0.59) $ 3.26

Page 7

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

Twelve Months Ended September 30, 2025

Reported (GAAP) Purchase accounting adjustments

(A) Integration costs

(B) Restructuring costs

(B) Transaction costs

(D) Product, litigation, and other items

(E) TSA/LSA total Income tax benefit of special items Adjusted

(Non-GAAP)

See Footnotes on Page 10

REVENUES $ 18,544 $ — $ — $ — $ — $ — $ — $ — $ — $ 18,544

Gross margin 8,258 1,867 — — — — 115 — — 10,241

Selling and administrative expense 4,643 (2) — — — — (33) — — 4,609

Research and development expense 970 — — — — — (15) — — 955

OPERATING INCOME 1,941 1,869 127 270 6 3 463 (12) — 4,666

Net interest expense (577) (4) — — — — — — — (582)

Other (expense) income, net (105) — — — — — 43 12 — (50)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 1,258 1,865 127 270 6 3 506 — — 4,034

Income tax provision 158 — — — — — — — 443 601

NET INCOME FROM CONTINUING OPERATIONS $ 1,100 $ 1,865 $ 127 $ 270 $ 6 $ 3 $ 506 $ — $ (443) $ 3,433

DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS $ 3.81 $ 6.46 $ 0.44 $ 0.93 $ 0.02 $ 0.01 $ 1.75 $ — $ (1.54) $ 11.90

Page 8

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED RESULTS TO ADJUSTED RESULTS

(Unaudited; Amounts in millions, except per share data)

Twelve Months Ended September 30, 2024

Reported (GAAP) Purchase accounting adjustments

(A) Integration costs

(B) Restructuring costs

(B) Transaction costs

(D) Product, litigation, and other items

(E) European regulatory initiative-related costs

(F) TSA/LSA total Income tax benefit of special items Adjusted (Non-GAAP)

See Footnotes on Page 10

REVENUES $ 16,820 $ — $ — $ — $ — $ — $ — $ 67 $ — $ — $ — $ 16,887

Gross margin 7,448 1,482 — — — — — 115 43 — — 9,088

Selling and administrative expense 4,250 1 — — — — — (56) (1) — — 4,194

Research and development expense 896 — — — — — — (4) (54) — — 838

OPERATING INCOME 1,713 1,481 23 294 48 — 13 393 98 27 — 4,091

Net interest expense (366) (5) — — — (8) — — — — — (379)

Other expense, net (20) — — — — — — (51) — (27) — (98)

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 1,327 1,477 23 294 48 (8) 13 342 98 — — 3,614

Income tax provision 273 — — — — — — — — — 267 540

NET INCOME FROM CONTINUING OPERATIONS $ 1,054 $ 1,477 $ 23 $ 294 $ 48 $ (8) $ 13 $ 342 $ 98 $ — $ (267) $ 3,074

DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS $ 3.62 $ 5.07 $ 0.08 $ 1.01 $ 0.17 $ (0.03) $ 0.05 $ 1.17 $ 0.34 $ — $ (0.92) $ 10.56

Page 9

The reconciliations of reported results to adjusted results on the previous pages reflect the following adjustments that are considered by management to be outside of BD’s underlying operational results or that affect period-to-period comparability:

(A)Includes amortization and other adjustments related to the purchase accounting for acquisitions. BD’s amortization expense is primarily recorded in Cost of products sold.

(B)Represents costs associated with integration and restructuring activities. These costs are recorded to Integration, restructuring and transaction expense.

(C)Represents transaction costs and financing impacts incurred in connection with the Advanced Patient Monitoring acquisition. The transaction costs are recorded to Integration, restructuring and transaction expense, and the financing impacts are recorded to Interest expense and Interest income.

(D)Amounts in fiscal years 2026 and 2025 represent costs incurred in connection with the separation of BD's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation. The amount in fiscal year 2024 represents costs incurred in connection with the separation of BD's former Diabetes Care business. These costs are recorded to Other operating expense, net.

(E)Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amounts presented include the following:

•Charges of $297 million in fiscal year 2025 related to product liability and certain other legal matters, recorded to Other operating expense, net. The amount in fiscal year 2024 reflects charges related to product liability and certain other legal matters, recorded to Other operating expense, net, including a $175 million charge to accrue an estimated liability for the SEC investigation with respect to, among other things, certain reporting issues involving BD AlarisTM infusion pumps included in SEC disclosures prior to 2021.

•Charges to adjust the estimate of future product remediation costs, recorded to Cost of products sold, of $98 million and $38 million in fiscal years 2025 and 2024, respectively.

•Charges related to pension settlement costs, recorded to Other expense, net, of $38 million in fiscal year 2025.

•The recognition of $67 million in accruals in fiscal year 2024 as an impact to Revenues relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024.

(F)Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are primarily recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.

Page 10

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover Page

Apr. 02, 2026

Entity Information [Line Items]

Document Type

8-K

Document Period End Date

Apr. 02, 2026

Entity Registrant Name

BECTON, DICKINSON AND COMPANY

Entity Central Index Key

0000010795

Amendment Flag

false

Entity Incorporation, State or Country Code

Entity File Number

001-4802

Entity Tax Identification Number

22-0760120

Entity Address, Address Line One

1 Becton Drive,

Entity Address, City or Town

Franklin Lakes,

Entity Address, State or Province

Entity Address, Postal Zip Code

07417-1880

City Area Code

(201)

Local Phone Number

847-6800

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security

Common stock, par value $1.00

Trading Symbol

BDX

Security Exchange Name

NYSE

Notes 1.900% due December 15, 2026 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security

1.900% Notes due December 15, 2026

Trading Symbol

BDX26

Security Exchange Name

NYSE

Notes 1.208% due June 4, 2026 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security

1.208% Notes due June 4, 2026

Trading Symbol

BDX/26A

Security Exchange Name

NYSE

Notes 1.213% due February 12, 2036 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security

1.213% Notes due February 12, 2036

Trading Symbol

BDX/36

Security Exchange Name

NYSE

Notes 3.519% due February 8, 2031 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security

3.519% Notes due February 8, 2031

Trading Symbol

BDX31

Security Exchange Name

NYSE

Notes 3.828% due June 7, 2032 | NEW YORK STOCK EXCHANGE, INC.

Entity Information [Line Items]

Title of 12(b) Security

3.828% Notes due June 7, 2032

Trading Symbol

BDX32A

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

dei_EntityListingsExchangeAxis=exch_XNYS

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=bdx_Notes1.900dueDecember152026Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=bdx_Notes1.208dueJune42026Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=bdx_Notes1213DueFebruary122036Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=bdx_Notes3.519DueFebruary82031Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=bdx_Notes3.828DueJune72032Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: